2,088,937 Shares in Protara Therapeutics, Inc. (NASDAQ:TARA) Acquired by Toronto Dominion Bank

Toronto Dominion Bank bought a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,088,937 shares of the company's stock, valued at approximately $11,030,000. Toronto Dominion Bank owned about 10.13% of Protara Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of TARA. HBK Investments L P acquired a new position in shares of Protara Therapeutics in the fourth quarter valued at $106,000. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics during the 4th quarter worth about $111,000. Bailard Inc. bought a new stake in shares of Protara Therapeutics during the 4th quarter worth about $157,000. Commonwealth Equity Services LLC grew its stake in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. Finally, 683 Capital Management LLC bought a new position in Protara Therapeutics in the 4th quarter valued at about $330,000. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Stock Down 1.3%

Shares of NASDAQ:TARA traded down $0.04 during trading on Monday, reaching $3.13. 372,832 shares of the company traded hands, compared to its average volume of 772,980. The firm has a market capitalization of $120.76 million, a PE ratio of -1.11 and a beta of 1.73. Protara Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $10.48. The company's 50 day moving average is $3.83 and its two-hundred day moving average is $4.17.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.18. As a group, research analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Insider Activity

In related news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the transaction, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 8.40% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TARA. Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Monday, April 28th. Scotiabank initiated coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating for the company. Finally, Jones Trading upgraded shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $20.50.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.